share_log

C.Q. Pharmaceutical Holding Co., Ltd.'s (SZSE:000950) Last Week's 5.5% Decline Must Have Disappointed Private Companies Who Have a Significant Stake

Simply Wall St ·  Jun 25 18:36

Key Insights

  • Significant control over C.Q. Pharmaceutical Holding by private companies implies that the general public has more power to influence management and governance-related decisions
  • The top 2 shareholders own 55% of the company
  • Using data from company's past performance alongside ownership research, one can better assess the future performance of a company

Every investor in C.Q. Pharmaceutical Holding Co., Ltd. (SZSE:000950) should be aware of the most powerful shareholder groups. We can see that private companies own the lion's share in the company with 57% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

And last week, private companies endured the biggest losses as the stock fell by 5.5%.

Let's take a closer look to see what the different types of shareholders can tell us about C.Q. Pharmaceutical Holding.

ownership-breakdown
SZSE:000950 Ownership Breakdown June 25th 2024

What Does The Institutional Ownership Tell Us About C.Q. Pharmaceutical Holding?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

C.Q. Pharmaceutical Holding already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of C.Q. Pharmaceutical Holding, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
SZSE:000950 Earnings and Revenue Growth June 25th 2024

Hedge funds don't have many shares in C.Q. Pharmaceutical Holding. Our data shows that Chongqing Pharmaceutical Health Industry Co., Ltd. is the largest shareholder with 38% of shares outstanding. Chongqing City Construction Investment (Group) Co.,Ltd is the second largest shareholder owning 16% of common stock, and Chongqing Yufu Capital Equity Investment Fund Management Co. holds about 3.2% of the company stock.

A more detailed study of the shareholder registry showed us that 2 of the top shareholders have a considerable amount of ownership in the company, via their 55% stake.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is some analyst coverage of the stock, but it could still become more well known, with time.

Insider Ownership Of C.Q. Pharmaceutical Holding

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

Our data suggests that insiders own under 1% of C.Q. Pharmaceutical Holding Co., Ltd. in their own names. However, it's possible that insiders might have an indirect interest through a more complex structure. It is a pretty big company, so it would be possible for board members to own a meaningful interest in the company, without owning much of a proportional interest. In this case, they own around CN¥5.3m worth of shares (at current prices). It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling.

General Public Ownership

The general public, who are usually individual investors, hold a 30% stake in C.Q. Pharmaceutical Holding. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Company Ownership

Our data indicates that Private Companies hold 57%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

Public Company Ownership

It appears to us that public companies own 3.9% of C.Q. Pharmaceutical Holding. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. For instance, we've identified 3 warning signs for C.Q. Pharmaceutical Holding (1 makes us a bit uncomfortable) that you should be aware of.

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment